Berghmans T, Meert A P
Service des Soins intensifs et Urgences oncologiques & Oncologie thoracique, Institut Jules Bordet, Centre des Tumeurs, ULB.
Rev Med Brux. 2017;38(3):175-177.
Immunotherapy renews in non-small cell lung cancer. Antibodies directed against PD1 and PD-L1, blocking the relationship between the cancer cells and the immune system, allowed in randomised trials to significantly improve cancer control with an interesting survival impact of treated patients. However, it remains to determine the most benefiting populations from this expensive and potentially toxic therapy.
免疫疗法在非小细胞肺癌中得以复兴。针对PD1和PD-L1的抗体阻断癌细胞与免疫系统之间的关联，在随机试验中可显著改善癌症控制情况，并对接受治疗的患者的生存产生有利影响。然而，仍有待确定从这种昂贵且具有潜在毒性的疗法中获益最大的人群。
